These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
825 related articles for article (PubMed ID: 28093061)
1. Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway. Zheng R; Jiang H; Li J; Liu X; Xu H Curr Cancer Drug Targets; 2017; 17(4):376-385. PubMed ID: 28093061 [TBL] [Abstract][Full Text] [Related]
2. Anticancer Effects of Paris Saponins by Apoptosis and PI3K/AKT Pathway in Gefitinib-Resistant Non-Small Cell Lung Cancer. Zhu X; Jiang H; Li J; Xu J; Fei Z Med Sci Monit; 2016 Apr; 22():1435-41. PubMed ID: 27125283 [TBL] [Abstract][Full Text] [Related]
3. Polyphyllin VII increases sensitivity to gefitinib by modulating the elevation of P21 in acquired gefitinib resistant non-small cell lung cancer. Wang H; Fei Z; Jiang H J Pharmacol Sci; 2017 Jul; 134(3):190-196. PubMed ID: 28757172 [TBL] [Abstract][Full Text] [Related]
4. miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1. Zhou G; Zhang F; Guo Y; Huang J; Xie Y; Yue S; Chen M; Jiang H; Li M Biomed Pharmacother; 2017 Jan; 85():113-119. PubMed ID: 27930974 [TBL] [Abstract][Full Text] [Related]
5. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474 [TBL] [Abstract][Full Text] [Related]
6. Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway. Wu H; Fan F; Liu Z; Shen C; Wang A; Lu Y Cancer Chemother Pharmacol; 2015 Aug; 76(2):307-15. PubMed ID: 26063323 [TBL] [Abstract][Full Text] [Related]
7. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer. Gadgeel SM; Wozniak A Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287 [TBL] [Abstract][Full Text] [Related]
8. Extracellular vesicles shed from gefitinib-resistant nonsmall cell lung cancer regulate the tumor microenvironment. Choi DY; You S; Jung JH; Lee JC; Rho JK; Lee KY; Freeman MR; Kim KP; Kim J Proteomics; 2014 Aug; 14(16):1845-56. PubMed ID: 24946052 [TBL] [Abstract][Full Text] [Related]
9. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines. Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177 [TBL] [Abstract][Full Text] [Related]
10. BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells. Yu Y; Xiao Z; Lei C; Ma C; Ding L; Tang Q; He Y; Chen Y; Chang X; Zhu Y; Zhang H BMC Cancer; 2023 Aug; 23(1):732. PubMed ID: 37553597 [TBL] [Abstract][Full Text] [Related]
11. AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations. Zhao R; Zhou S; Xia B; Zhang CY; Hai P; Zhe H; Wang YY BMC Cancer; 2016 Jul; 16():491. PubMed ID: 27431492 [TBL] [Abstract][Full Text] [Related]
12. Capilliposide from Lysimachia capillipes inhibits AKT activation and restores gefitinib sensitivity in human non-small cell lung cancer cells with acquired gefitinib resistance. Zhang SR; Xu YS; Jin E; Zhu LC; Xia B; Chen XF; Li FZ; Ma SL Acta Pharmacol Sin; 2017 Jan; 38(1):100-109. PubMed ID: 27840409 [TBL] [Abstract][Full Text] [Related]
13. Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds. Huang Y; Chen Y; Mei Q; Chen Y; Yu S; Xia S Oncol Rep; 2013 Jun; 29(6):2486-92. PubMed ID: 23525575 [TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models. Qu Y; Wu X; Yin Y; Yang Y; Ma D; Li H J Exp Clin Cancer Res; 2014 Jun; 33(1):52. PubMed ID: 24939055 [TBL] [Abstract][Full Text] [Related]
15. Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells. Han SY; Zhao MB; Zhuang GB; Li PP Lung Cancer; 2012 Jan; 75(1):30-7. PubMed ID: 21757251 [TBL] [Abstract][Full Text] [Related]
16. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism. Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738 [TBL] [Abstract][Full Text] [Related]
17. Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Wu M; Yuan Y; Pan YY; Zhang Y Mol Med Rep; 2014 Aug; 10(2):931-8. PubMed ID: 24840891 [TBL] [Abstract][Full Text] [Related]
18. Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT. Yang J; Qin G; Luo M; Chen J; Zhang Q; Li L; Pan L; Qin S Cell Death Dis; 2015 Jul; 6(7):e1829. PubMed ID: 26203858 [TBL] [Abstract][Full Text] [Related]
19. PARP1 promotes EGFR-TKI drug-resistance via PI3K/AKT pathway in non-small-cell lung cancer. Xu X; Liu Y; Gong Q; Ma L; Wei W; Zhao L; Luo Z Cancer Chemother Pharmacol; 2024 Aug; 94(2):209-221. PubMed ID: 38609654 [TBL] [Abstract][Full Text] [Related]
20. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway. Zhou J; Kwak KJ; Wu Z; Yang D; Li J; Chang M; Song Y; Zeng H; Lee LJ; Hu J; Bai C Cell Physiol Biochem; 2018; 47(5):1909-1924. PubMed ID: 29961070 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]